BCBA/AMGN (BCBA/AMGN)

Buenos Aires Stock Exchange: BCBA/AMGN · ARS

ARS 24,640

-171.20 (-0.7%)· Recorded snapshot

Market cap	372.5T
Revenue (ttm)	56.4T
Net income (ttm)	13T
EPS (ttm)	ARS 825
P/E (trailing)	29.9x
P/E (forward)	18.9x
Dividend	ARS 307 (1.25%)
Volume	1,027
Beta	0.41

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 56.4T
Net income (ttm): 13T
EPS (ttm): ARS 825
P/E (trailing): 29.9x
P/E (forward): 18.9x
Market cap: 372.5T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E18.9

P25 15P50 18.3P75 23.8

Trailing P/E29.9

P25 25.1P50 32.2P75 41.5

ROE91.5

P25 5P50 10.6P75 23.5

ROIC19.8

P25 7.2P50 13.5P75 19.8

Benchmarks · 1M

All BCBA/AMGN indicators

Market & fundamental data

Available fields

252

Groups with data

Currency

USD

Showing 252 of 252 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	ARS
Country	United States
Country code	AR
Earnings date	2026-11-03
Employees	31,500
Employees change	1,300
Employees growth	4.87%
Enterprise value	ARS 439.1T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	1980
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	ARDEUT110665
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	2024-01-24
Last stock split type	Forward
Market cap	ARS 372.5T
Next earnings date	2026-11-03
Price	ARS 24,640.00
Price currency	ARS
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-27
Symbol	bcba/AMGN
Website	https://www.amgen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	25.24x
Average P/E ratio (3Y)	29.44x
Average P/E ratio (5Y)	25.49x
Earnings yield	3.35%
EV/Earnings	33.9x
EV/EBIT	22.44x
EV/EBITDA	16.29x
EV/FCF	29.13x
EV/Sales	7.49x
FCF / EV yield	3.43%
FCF yield	4.05%
Forward P/E	18.88x
Graham number	4698.83137
Graham upside	-80.93%
Lynch fair value	ARS 7,503.02
Lynch upside	-69.55%
P/(FCF - SBC) ratio	25.97x
P/(OCF - SBC) ratio	20.98x
P/B ratio	21.51x
P/E ratio	29.86x
P/FCF ratio	24.71x
P/OCF ratio	20.15x
P/S ratio	6.6x
Price/EBITDA ratio	14.56x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	33.4%
EBITDA margin	45.33%
Effective tax rate	15.01%
FCF margin	25.72%
Gross margin	71.89%
Operating margin	33.4%
Pretax margin	27%
Profit margin	22.95%
Profit per employee	ARS 411.2M
Profitable quarters	9
Profitable years	23
Revenue per employee	ARS 1.8B
ROA	8.67%
ROA (5Y)	8.22%
ROCE	18.14%
ROE	91.47%
ROE (5Y)	101.82%
ROIC	19.76%
ROIC (5Y)	20.52%
SBC / revenue	1.29%
Tax / revenue	4.05%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	31.6%
EPS growth (Q)	64.91%
EPS growth (QoQ)	30.84%
EPS growth 10Y	5.12%
EPS growth 3Y	2.72%
EPS growth 5Y	10.3%
EPS growth quarters	6
EPS growth years	1
FCF growth	-4.06%
FCF growth (Q)	82.58%
FCF growth (QoQ)	136.22%
FCF growth 3Y	1.66%
FCF growth 5Y	2.72%
Gross profit growth	13.09%
Gross profit growth (Q)	12.23%
Gross profit growth 3Y	11.58%
Gross profit growth 5Y	7.36%
Net income growth	32.09%
Net income growth (Q)	65.85%
Net income growth (QoQ)	30.57%
Net income growth 3Y	3.09%
Net income growth 5Y	8.76%
Net income growth quarters	6
Net income growth years	1
OCF growth	3.87%
OCF growth (Q)	75.53%
OCF growth (QoQ)	82.82%
OCF growth 10Y	2.7%
OCF growth 3Y	4.93%
OCF growth 5Y	5.48%
Operating income growth	19.55%
Operating income growth (Q)	19.33%
Operating income growth 3Y	8.67%
Operating income growth 5Y	6.56%
Revenue growth	9.1%
Revenue growth (Q)	9.53%
Revenue growth (QoQ)	16.66%
Revenue growth 10Y	5.42%
Revenue growth 3Y	12.74%
Revenue growth 5Y	8.37%
Revenue growth quarters	13
Revenue growth years	6

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	ARS -3.4T
Depreciation and amortization	ARS 7T
EBIT	ARS 18.9T
EBITDA	ARS 25.6T
EPS	ARS 825.26
Financing cash flow	ARS -6.1T
Free cash flow	ARS 15.1T
Free cash flow minus SBC	ARS 14.3T
Gross profit	ARS 40.6T
Income taxes	ARS 2.3T
Investing cash flow	ARS -3.5T
Net borrowing	ARS 2T
Net cash flow	ARS 8.8T
Net income	ARS 13T
Operating cash flow minus SBC	ARS 17.8T
Operating income	ARS 18.9T
Revenue	ARS 56.4T
Stock-based compensation	ARS 728.9B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.89
Book value per share	ARS 32,030.65
Debt / EBITDA	3.27
Debt / equity	4.9
Debt / FCF	5.63
Goodwill	ARS 28.7T
Interest coverage	4.14
Long-term assets	ARS 87.9T
Long-term liabilities	ARS 85.1T
Net cash (debt)	ARS -64.2T
Net cash / market cap	-17.23%
Net debt / EBITDA	2.51
Net debt / equity	3.71
Net debt / FCF	4.26
Piotroski F-Score	8
Property, plant and equipment	ARS 13.1T
Shareholders' equity	ARS 17.3T
Tangible book value	ARS -40.7T
Tangible book value per share	ARS -75,272.59
Total assets	ARS 141.7T
Total cash	ARS 20.7T
Total debt	ARS 84.9T
Total liabilities	ARS 124.4T
WACC	6.13%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.42
Current assets	ARS 53.8T
Current liabilities	ARS 39.2T
Current ratio	1.37
Inventory turnover	1.67
Net working capital	ARS 1.4T
Quick ratio	0.95
Working capital	ARS 14T
Working capital turnover	7,181.74

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.46%
Dividend growth	34.03%
Dividend growth (10Y)	76.59%
Dividend growth (3Y)	93.36%
Dividend growth (5Y)	89.02%
Dividend growth years	14
Dividend payment date	2026-09-11
Dividend payment years	16
Dividend payout frequency	Quarterly
Dividend per share	ARS 306.73
Dividend yield	1.25%
Ex-dividend date	2026-08-21
Last dividend	ARS 81.67
Payout ratio	60.45%
Shareholder yield	0.78%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	ARS 19,495.53
1D price change	-0.69%
1M price change	10.2%
1M total return	10.2%
1W price change	7.22%
1W total return	7.22%
1Y price change	62.11%
1Y return CAGR	65.23%
1Y total return	65.17%
20-day SMA	ARS 22,960.50
200-day SMA	ARS 19,049.85
3M price change	23.08%
3M total return	23.76%
3Y price change	214.55%
3Y return CAGR	49.03%
3Y total return	231.09%
50-day SMA	ARS 22,438.60
50-day SMA vs 200-day SMA	50over200
52-week high	ARS 25,140.00
52-week high date	2026-10-26
52-week low	ARS 12,320.00
52-week low date	2025-10-27
5Y price change	1,656.45%
5Y return CAGR	79.97%
5Y total return	1,787.17%
6M price change	42.76%
6M total return	44.21%
All-time high	ARS 25,140.00
All-time high date	2026-10-26
All-time low	ARS 273.67
All-time low date	2019-07-31
Average true range (ATR)	ARS 602.51
Average volume	2.6K
Beta (5Y)	0.41
Change from 52-week high	-1.99%
Change from 52-week low	100%
Change from all-time high	-1.99%
Change from all-time low	8,903.64%
Change from open	-0.08%
Day's gap	-0.6%
Dollar volume	ARS 25.3M
High price	ARS 24,770.00
Low price	ARS 24,580.00
Monthly RSI	77.34
Open price	ARS 24,660.00
Position in 52-week range	31.58%
Previous close	ARS 24,810.00
Price vs 150-day SMA	26.39%
Price vs 20-day SMA	7.31%
Price vs 200-day SMA	29.34%
Price vs 50-day SMA	9.81%
Relative volume	0.39
RSI	67.52
Sharpe ratio	1.67
Sharpe ratio (3Y)	1.23
Sharpe ratio (5Y)	1.67
Sortino ratio	2.7
Sortino ratio (3Y)	1.96
Sortino ratio (5Y)	2.71
Volume	1K
Weekly RSI	68.84
YTD price change	47.81%
YTD total return	49.94%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	539.2M
Shares change (QoQ)	0%
Shares change (YoY)	0.46%
Shares held by insiders	0.17%
Shares held by institutions	83.8%
Short ratio	4.8 days

Deeper analysis on BCBA/AMGN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCBA/AMGN report

Is a complete BCBA/AMGN research report available?

No complete published report is available for bcba/AMGN (BCBA/AMGN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BCBA/AMGN (BCBA/AMGN)

Price

Financial snapshot

Fair-value bridge

Latest news · BCBA/AMGN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCBA/AMGN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BCBA/AMGN

Frequently asked questions